🔗 Share this article

The recently developed medications for gonorrhoea in decades are being hailed as a "major milestone" in the battle against superbug strains of the infection, according to researchers.

A Worldwide Challenge

The sexually transmitted infection are on the rise around the world, with data suggesting more than 82 million infections per year. Particularly high rates are observed in the African continent and countries within the World Health Organization's Western Pacific region, which encompasses China and Mongolia to New Zealand. Within England, cases have reached a record high, while figures across Europe in 2023 were three times higher compared to those in 2014.

“The clearance of fresh medications for gonorrhoea is an important and timely advancement in the face of increasing worldwide cases, the spread of superbugs and the very limited available drugs presently on offer.”

Health officials are particularly alarmed about the surge in antibiotic-resistant strains. The World Health Organization has designated it as a "high-priority threat". Ongoing monitoring found that the effectiveness of primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Drugs Gain Clearance

One new antibiotic, alternatively called a brand name, was authorized by the US FDA in December for combating gonorrhoea. This infection can lead to serious health problems, including infertility. Scientists believe that focused deployment of this new drug will help hinder the spread of drug resistance.

Another new antibiotic, created by the drugmaker GSK, gained clearance in the same week. This treatment, which is employed against urinary tract infections, was demonstrated in studies to be able to combat drug-resistant strains of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin emerged from a innovative non-profit model for antibiotic development. The non-profit organisation GARDP worked alongside the drug firm Innoviva to see it through.

“This milestone signifies a huge turning point in the therapy of superbug gonorrhoea, which up to this point has been evolving faster than antibiotic development.”

Testing Outcomes and Worldwide Availability

As per results detailed in a major medical journal, the new drug successfully treated over nine in ten of cases of the STI. This puts it on an comparable level with the typical regimen, which uses a dual-drug approach. The study included over 900 participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, the non-profit has the authority to make available and distribute the drug in numerous developing nations.

Doctors on the front lines have shared positive views. The availability of a one-pill regimen like this is described as a "revolutionary step" for public health efforts. This is deemed vital to lessen the impact of the illness for individuals and to stop the proliferation of untreatable gonorrhoea worldwide.